McDermott Will & Emery Advises BIOCORP on its Partnership with Aguettant


PARIS (November 21, 2016) — International law firm McDermott Will & Emery advised Biocorp, a French company specializing in the development and manufacture of innovative medical and drug delivery devices, on its strategic collaboration with Aguettant for the launch of Apokonnect .

Aguettant is a laboratory specialized in the development, manufacturing and commercialization of essential medicines for hospitals.

Apokonnect will combine the expertise of BIOCORP and Aguettant to improve the medical care and follow-up of patients suffering from Parkinson’s disease. The innovative Apokonnect project will rely both on Apokinon®, an apomorphine self-injection pen developed by Aguettant, and on Easylog, the connected device developed by Biocorp.

By gathering data related to patients’ treatment and symptoms on a tablet computer or smartphone via a secured app, this innovative treatment will not only help improve the treatment compliance and patients’ life, but will also increase their autonomy and lead to the development of “homecare” while staying connected to healthcare professional in real-time.

The McDermott team advising on the transaction was led by Paris-based partners Emmanuelle Trombe and Anthony Paronneau.

McDermott’s Life Sciences Group works with clients to structure collaborative arrangements among emerging life sciences companies, established pharmaceutical and biotech companies and researchers and research institutions. These arrangements range from licensing technology to and from academic medical centers, universities and other research institutions, to complex strategic alliances among life sciences companies to achieve varied financial, research and development, manufacturing and distribution objectives. The Firm’s long-term experience in advising pharmaceuticals and agrochemical companies on taxation issues allows us to devise structures and tax plans for life sciences companies who wish to be attractive partners or acquisition candidates for the pharmaceutical industry.

About McDermott Will & Emery
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, we have offices in Boston, Brussels, Chicago, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, DC. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.